Ethynylated Heterodinucleotide Cytostatic Drugs for a better Cancer Therapy
Our invention describes so called duplex drugs by using phosphodiester bounding as a linker between two nucleoside analogues. Their in vivo metabolism delivers a mixture of highly active antimetabolites. First experimental data demonstrate advantages of our duplex drugs compared to classical nucleoside analogues against some types of cancer cells.
Further Information: PDF
Eberhard Karls Universität Tübingen
Phone: +49 (7071) 29-72639
Contact
Dr. Rolf Hecker
Media Contact
All latest news from the category: Technology Offerings
Newest articles
FDmiX: Fast, robust series production of nanoparticles
Nucleic acid-based medications such as mRNA vaccines are opening up new therapeutic approaches. These active ingredients must be enclosed inside nanoparticles to ensure that they get to where they are…
Sensor measures oxygen content of breath
Oxygen saturation in the blood that is either too low or too high can cause physical harm or even death. This is why patients’ oxygen concentraions are monitored continuously in…
Laser immersion probe for smart inline monitoring of water and wastewater
A new type of laser-based immersion probe, which the Fraunhofer Institute for Laser Technology ILT in Aachen is testing as part of BMBF- and EU-funded projects with industrial partners and…
